Get the Stockscreener App
16.37
6.24%
-1.09
Pre-market:
16.61
0.24
+1.47%
Lyell Immunopharma Inc stock is traded at $16.37, with a volume of 134.04K.
It is down -6.24% in the last 24 hours and down -26.95% over the past month.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
See More
Previous Close:
$17.46
Open:
$17.46
24h Volume:
134.04K
Relative Volume:
1.51
Market Cap:
$381.98M
Revenue:
$36,000
Net Income/Loss:
$-274.45M
P/E Ratio:
-1.3861
EPS:
-11.8105
Net Cash Flow:
$-150.80M
1W Performance:
+1.49%
1M Performance:
-26.95%
6M Performance:
-32.94%
1Y Performance:
+95.77%
1-Day Range:
$16.09
$17.65
1-Week Range:
$16.09
$17.69
52-Week Range:
$7.65
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
16.37 | 407.41M | 36,000 | -274.45M | -150.80M | -11.81 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Needham | Buy |
| Mar-09-26 | Initiated | Citizens | Mkt Outperform |
| Dec-09-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances - Yahoo Finance
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL) - MSN
Lyell Immunopharma stock (US55083R1041): Analyst boosts price target as cell therapy pipeline advanc - AD HOC NEWS
ARCH funds and directors disclose shared control of 3.25M LYEL shares (LYEL) - Stock Titan
Lyell Immunopharma (LYEL) Slips -6.23%, Testing $16.95 Support 2026-05-15Crowd Breakout Signals - newser.com
Lyell Immunopharma (LYEL) Delivers Q1 2026 Beat — EPS $-1.10 vs $-2.41 ExpectedOperating Margin - Newser
LYEL Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Lyell Immunopharma to Participate in Investor Conferences During May - geneonline.com
Lyell Immunopharma Announces Participation in May Investor Conferences | Associated Press | syndication news - Enidnews.com
Cancer cell therapy firm Lyell offers investor talks online May 19–20 - Stock Titan
TradingKey - TradingKey
Lyell Immunopharma (LYEL) entities each report 4.3% ownership in amended 13G - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Upgraded to Hold at Wall Street Zen - MarketBeat
Explore Investments/Jeff Bezos report 6.6% stake in Lyell (LYEL) - Stock Titan
Lyell Records $24 Mln Loss In Q1, Provides Updates On CAR-T Cell Therapies For Cancer Treatment - RTTNews
Lyell Immunopharma: Q1 Earnings Snapshot - theheraldreview.com
Lyell starts Phase 3 lymphoma dosing, says cash runway reaches Q3 2027 - Stock Titan
Lyell Immunopharma (NASDAQ: LYEL) cuts quarterly loss and raises equity capital - Stock Titan
Lyell Immunopharma (NASDAQ: LYEL) trims Q1 loss and advances CAR T trials - Stock Titan
BRIEF-Lyell Immunopharma Q1 Net Income USD -24.153 Million - TradingView
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 - GlobeNewswire
Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Tuesday - MarketBeat
Lyell Immunopharma (LYEL) Price Target Increased by 27.27% to 14.28 - MSN
LYEL SEC FilingsLyell Immunopharma, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
BofA Securities Maintains Lyell Immunopharma(LYEL.US) With Sell Rating, Maintains Target Price $12 - Moomoo
Lyell Immunopharma (NASDAQ:LYEL) Upgraded by Robert W. Baird to Strong-Buy Rating - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Baird initiates Lyell Immunopharma stock with outperform rating By Investing.com - Investing.com South Africa
Baird initiates Lyell Immunopharma stock with outperform rating - Investing.com
Baird Maintains Lyell Immunopharma(LYEL.US) With Buy Rating, Maintains Target Price $49 - Moomoo
BofA reiterates Lyell Immunopharma stock Underperform on rival exit By Investing.com - Investing.com Canada
BofA reiterates Lyell Immunopharma stock Underperform on rival exit - Investing.com
Baird Initiates Lyell Immunopharma(LYEL.US) With Buy Rating, Announces Target Price $49 - Moomoo
Lyell Immunopharma climbs after reporting strong CAR T-cell therapy results - MSN
[ARS] Lyell Immunopharma, Inc. SEC Filing - Stock Titan
Lyell Immunopharma (NASDAQ: LYEL) outlines 2026 virtual meeting, board elections and pay vote - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap DownHere's What Happened - MarketBeat
LYEL (Lyell Immunopharma Inc.) reports far wider than expected Q4 2025 loss as shares tick modestly higher.Pro Level Trade Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Euler Fund (NASDAQ: LYEL) holds 1,426,528 shares, 6.71% stake disclosed - Stock Titan
Lyell Immunopharma (LYEL) Stock: Gaining Traction? (Underperforming) 2026-04-20Retail Money Flow - UBND thành phố Hải Phòng
Lyell Immunopharma (NASDAQ:LYEL) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Increase in Short Interest - MarketBeat
LYEL Earnings History & Surprises | EPS & Revenue Results | LYELL IMMUNOPHARMA INC (NASDAQ:LYEL) - ChartMill
A First Look At Lyell Immunopharma (NASDAQ:LYEL) - Seeking Alpha
[EFFECT] Lyell Immunopharma, Inc. SEC Filing - Stock Titan
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel - The Manila Times
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4%Should You Sell? - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 6.9%Should You Buy? - MarketBeat
This WhiteFiber Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Sahm
Needham initiates coverage of Lyell Immunopharma (LYEL) with buy recommendation - MSN
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):